AngioDynamics Improves VenaCure - Analyst Blog

Therapeutic and diagnostic devices maker AngioDynamics Inc. (ANGO) has expanded its VenaCure EVLT laser vein treatment with the launch of a new access kit, which will reduce both procedure time and steps for physicians using VenaCure’s NeverTouch laser fiber to treat varicose veins (abnormally swollen veins), a condition affecting more than 40 million Americans annually.

The new access kit, which is equipped with a 0.018 inch long-access wire, trims the number of steps (from 8 to 4) to gain access for the VenaCure EVLT procedure. Besides, the faster procedure time enabled by the kit will lead to improved patient comfort.

VenaCure EVLT, which includes DELTA series laser, procedure kits, accessories and a delivery system, offers patients a safe, minimally-invasive and effective option for treating the source of varicose veins while offering fast recovery. It continues to be the most preferred laser vein treatment in the market.

VenaCure EVLT addresses the high-growth venous intervention market, representing an attractive opportunity for AngioDynamics. Incremental sales from the system drove double-digit revenue growth at the company’s Peripheral Vascular unit in fiscal 2010 (ended May 31, 2010). Expanded penetration of VenaCure EVLT in the U.S. will continue to be a growth engine in the forthcoming reporting periods.

AngioDynamics is engaged in the designing, development, manufacture, and marketing of therapeutic and diagnostic devices to treat peripheral vascular disease (PVD) and other non-coronary diseases.

The company has market leading positions in several of its operating segments including angiographic products and thrombolytic catheters and products. AngioDynamics continues to broaden its product portfolio having launched 11 new products in fiscal 2010. The company’s product lines face strong challenges from the competitive offerings of its larger rivals such as Boston Scientific (BSX) and C.R. Bard (BCR).

AngioDynamics’ focus on interventional peripheral products is expected to help drive future growth. The company should continue to benefit from the ongoing shift from open surgery to less invasive interventional procedures. We currently maintain a Neutral recommendation on AngioDynamics.